Literature DB >> 10567584

Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin.

K A Browne1, E Blink, V R Sutton, C J Froelich, D A Jans, J A Trapani.   

Abstract

Granule-mediated cell killing by cytotoxic lymphocytes requires the combined actions of a membranolytic protein, perforin, and granule-associated granzymes, but the mechanism by which they jointly kill cells is poorly understood. We have tested a series of membrane-disruptive agents including bacterial pore-forming toxins and hemolytic complement for their ability to replace perforin in facilitating granzyme B-mediated cell death. As with perforin, low concentrations of streptolysin O and pneumolysin (causing <10% (51)Cr release) permitted granzyme B-dependent apoptosis of Jurkat and Yac-1 cells, but staphylococcal alpha-toxin and complement were ineffective, regardless of concentration. The ensuing nuclear apoptotic damage was caspase dependent and included cleavage of poly(ADP-ribose) polymerase, suggesting a mode of action similar to that of perforin. The plasma membrane lesions formed at low dose by perforin, pneumolysin, and streptolysin did not permit diffusion of fluorescein-labeled proteins as small as 8 kDa into the cell, indicating that large membrane defects are not necessary for granzymes (32 to 65 kDa) to enter the cytosol and induce apoptosis. The endosomolytic toxin, listeriolysin O, also effected granzyme B-mediated cell death at concentrations which produced no appreciable cell membrane damage. Cells pretreated with inhibitors of endosomal trafficking such as brefeldin A took up granzyme B normally but demonstrated seriously impaired nuclear targeting of granzyme B when perforin was also added, indicating that an important role of perforin is to disrupt vesicular protein trafficking. Surprisingly, cells exposed to granzyme B with perforin concentrations that produced nearly maximal (51)Cr release (1,600 U/ml) also underwent apoptosis despite excluding a 8-kDa fluorescein-labeled protein marker. Only at concentrations of >4,000 U/ml were perforin pores demonstrably large enough to account for transmembrane diffusion of granzyme B. We conclude that pore formation may allow granzyme B direct cytosolic access only when perforin is delivered at very high concentrations, while perforin's ability to disrupt endosomal trafficking may be crucial when it is present at lower concentrations or in killing cells that efficiently repair perforin pores.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10567584      PMCID: PMC84991          DOI: 10.1128/MCB.19.12.8604

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  48 in total

1.  Target cell lysis by CTL granule exocytosis is independent of ICE/Ced-3 family proteases.

Authors:  A Sarin; M S Williams; M A Alexander-Miller; J A Berzofsky; C M Zacharchuk; P A Henkart
Journal:  Immunity       Date:  1997-02       Impact factor: 31.745

2.  Brefeldin A's effects on endosomes, lysosomes, and the TGN suggest a general mechanism for regulating organelle structure and membrane traffic.

Authors:  J Lippincott-Schwartz; L Yuan; C Tipper; M Amherdt; L Orci; R D Klausner
Journal:  Cell       Date:  1991-11-01       Impact factor: 41.582

3.  Functional size of complement and perforin pores compared by confocal laser scanning microscopy and fluorescence microphotolysis.

Authors:  H Sauer; L Pratsch; J Tschopp; S Bhakdi; R Peters
Journal:  Biochim Biophys Acta       Date:  1991-03-18

4.  Nuclear transport of granzyme B (fragmentin-2). Dependence of perforin in vivo and cytosolic factors in vitro.

Authors:  D A Jans; P Jans; L J Briggs; V Sutton; J A Trapani
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

5.  Human perforin: rapid enrichment by immobilized metal affinity chromatography (IMAC) for whole cell cytotoxicity assays.

Authors:  C J Froelich; J Turbov; W Hanna
Journal:  Biochem Biophys Res Commun       Date:  1996-12-04       Impact factor: 3.575

6.  Processing of the Nedd2 precursor by ICE-like proteases and granzyme B.

Authors:  N L Harvey; J A Trapani; T Fernandes-Alnemri; G Litwack; E S Alnemri; S Kumar
Journal:  Genes Cells       Date:  1996-07       Impact factor: 1.891

Review 7.  Alpha-toxin of Staphylococcus aureus.

Authors:  S Bhakdi; J Tranum-Jensen
Journal:  Microbiol Rev       Date:  1991-12

8.  Attenuated mutants of the intracellular bacterium Listeria monocytogenes obtained by single amino acid substitutions in listeriolysin O.

Authors:  E Michel; K A Reich; R Favier; P Berche; P Cossart
Journal:  Mol Microbiol       Date:  1990-12       Impact factor: 3.501

9.  Granzyme B (GraB) autonomously crosses the cell membrane and perforin initiates apoptosis and GraB nuclear localization.

Authors:  L Shi; S Mai; S Israels; K Browne; J A Trapani; A H Greenberg
Journal:  J Exp Med       Date:  1997-03-03       Impact factor: 14.307

10.  A natural killer cell granule protein that induces DNA fragmentation and apoptosis.

Authors:  L Shi; R P Kraut; R Aebersold; A H Greenberg
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

View more
  43 in total

Review 1.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

2.  Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors:  Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal:  Mol Immunol       Date:  2018-11-30       Impact factor: 4.407

Review 3.  Death by a thousand cuts: granzyme pathways of programmed cell death.

Authors:  Dipanjan Chowdhury; Judy Lieberman
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

Review 4.  Are BiTEs the "missing link" in cancer therapy?

Authors:  Carter M Suryadevara; Patrick C Gedeon; Luis Sanchez-Perez; Terence Verla; Christopher Alvarez-Breckenridge; Bryan D Choi; Peter E Fecci; John H Sampson
Journal:  Oncoimmunology       Date:  2015-04-30       Impact factor: 8.110

Review 5.  Perforin and granzymes: function, dysfunction and human pathology.

Authors:  Ilia Voskoboinik; James C Whisstock; Joseph A Trapani
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

6.  Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6.

Authors:  Siddheshvar Bhela; Christine Kempsell; Monali Manohar; Margarita Dominguez-Villar; Russell Griffin; Pooja Bhatt; Pia Kivisakk-Webb; Robert Fuhlbrigge; Thomas Kupper; Howard Weiner; Clare Baecher-Allan
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

7.  Granzyme K-deficient mice show no evidence of impaired antiviral immunity.

Authors:  Lars T Joeckel; Cody C Allison; Marc Pellegrini; Catherina H Bird; Phillip I Bird
Journal:  Immunol Cell Biol       Date:  2017-04-21       Impact factor: 5.126

8.  Cationic sites on granzyme B contribute to cytotoxicity by promoting its uptake into target cells.

Authors:  Catherina H Bird; Jiuru Sun; Kheng Ung; Diana Karambalis; James C Whisstock; Joseph A Trapani; Phillip I Bird
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

9.  Granzyme A- and B-cluster deficiency delays acute lung injury in pneumovirus-infected mice.

Authors:  Reinout A Bem; Job B M van Woensel; Rene Lutter; Joseph B Domachowske; Jan Paul Medema; Helene F Rosenberg; Albert P Bos
Journal:  J Immunol       Date:  2009-12-16       Impact factor: 5.422

10.  WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy.

Authors:  Lillian Sun; Ellen Moore; Rose Berman; Paul E Clavijo; Anthony Saleh; Zhong Chen; Carter Van Waes; John Davies; Jay Friedman; Clint T Allen
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.